#USA #San Antonio #Breast Cancer #ClearCoast™ #ClearCut Medical

ClearCut Medical's Breakthrough in Breast Cancer Surgery

ClearCut Medical, a pioneering private company in the healthcare sector, has recently unveiled significant findings from a post-marketing study of its revolutionary ClearCoast™ system at the San Antonio Breast Cancer Symposium. The ClearCoast™ stands as the world’s first and only portable MRI technology specifically designed for real-time intraoperative assessment of tumor margins during breast-conserving surgeries. This advancement is crucial for minimizing the risk of cancer recurrence by ensuring clear surgical margins.

The primary focus of the study was to evaluate the proportion of patients requiring retreatment and compare the efficacy of ClearCoast™ against standard diagnostic methods. This analysis follows the guidelines set forth by SSO-ASTRO, emphasizing the importance of precise margin assessment in surgical oncology. With the secondary objectives geared towards measuring the system’s abilities in detecting positive margins and evaluating the total excised breast tissue, the findings have drawn significant attention.

Prof. Dr. Marc Thill, head of Gynecology and Gynecological Oncology at Agaplesion Markus Hospital in Frankfurt, Germany, remarked on the impressive capabilities of ClearCoast™. He stated, "This technique is the most promising method presently available for assessing margins intraoperatively in breast conserving surgery, especially for both in situ and invasive cancers. Following successful trials, I firmly believe that this technique is ready for routine clinical application."

In the study, ClearCoast™ demonstrated an impressive sensitivity rate of 81% and a specificity of 70%. Remarkably, it managed to detect 92% of ductal carcinoma in situ (DCIS) instances compared to just 18% achieved by the control standard. Moreover, surgeons using ClearCoast™ indicated they removed a lesser volume of breast tissue (averaging 69.9 cm³) than their counterparts relying on standard methods (averaging 153.2 cm³), all while maintaining similar procedure durations. This innovation suggests a potential 80% reduction in the need for re-excisions, highlighting the system's effectiveness and efficiency.

Hezi Himelfarb, CEO of ClearCut Medical, emphasized the significance of this development by stating, "These findings not only demonstrate the potential for decreasing patient re-excision rates but also aim to alleviate healthcare costs without compromising on precision or time efficiency. The ClearCoast™ system provides an intuitive interface, allowing surgeons to interpret images instantly, without needing further specialist input."

Recently receiving CE Mark approval, ClearCoast™ is now being marketed across Europe in partnership with pfm medical gmbh. As a dedicated enterprise focused on elevating cancer patient care, ClearCut Medical aims for their MRI technology to become a trusted asset in surgical environments. Utilizing a proprietary 1.2T MRI system, the ClearCoast™ efficiently assesses lumpectomy specimens through a unique disposable chamber integrated within the system. Its efficient design eliminates the need for special facilities or additional equipment interference, offering real-time quantitative insights through an easily interpretable topographic display.

Given the established high sensitivity and specificity from clinical trials, coupled with the potential for drastically lower re-excision rates, ClearCut Medical is set to redefine standards in breast cancer surgical practices. As this innovative technology grows, it opens up new pathways toward better patient outcomes in oncology.

In conclusion, ClearCut Medical's ClearCoast™ positions itself at the forefront of medical innovation, paving the way for enhanced surgical accuracy and ultimately better patient care in the field of breast cancer treatment. With ongoing studies and clinical applications, the future looks promising for both ClearCut Medical and the patients it serves.